The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 18 | 44.8x | 20.8x | Bottom tier | |
Growth | 94 | 47.4% | 6.1% | Top tier | |
Quality | 90 | 54.0% | 6.6% | Top tier | |
Safety | 77 | 0.5x | 0.7x | Top tier | |
Capital Return | 20 | 0.49% | 2.02% | Bottom tier | |
Momentum | 82 | 39.9% | 4.1% | Top tier | |
Sentiment | 68 | 16 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Eli Lilly and Company (LLY) is one of the world's leading pharmaceutical and healthcare companies, focusing on the discovery, development, manufacturing, and marketing of innovative therapies in vital areas including endocrinology and diabetes, oncology, immunology, and neuroscience. The company generates the bulk of its sales through its specialty medicines, particularly incretin mimetic obesity and diabetes treatments such as Mounjaro and Zepbound, alongside its rapid expansion into cancer, Alzheimer's, and autoimmune disease therapies through advanced therapeutic platforms.
During the first quarter of 2026, Eli Lilly achieved exceptional financial results, with total revenue jumping 56% compared to the prior-year quarter to reach $19.8 billion. Gross profit for the quarter was $16.2 billion, while net income recorded $7.4 billion with earnings per share (EPS) of $8.26 (non-GAAP EPS rose to $8.55 compared to $3.34 in the first quarter of 2025). This growth was driven by robust demand for Mounjaro and Zepbound, which achieved combined sales of $12.8 billion, contributing approximately $6.7 billion of the company's total growth.
The company maintained strong operational efficiency and profit margins, with the gross profit margin reaching 82.6%, declining slightly by one percentage point due to some pricing pressures. In contrast, the non-GAAP operating margin rose by 7 percentage points to 50%, benefiting from economies of scale resulting from sales growth. Based on this momentum, the company raised its full-year 2026 guidance, now expecting annual revenue to range between $82 billion and $85 billion (representing 28% growth compared to 2025), and non-GAAP EPS to range between $35.50 and $37.00.
Eli Lilly and Company stock currently trades within a 52-week range of $623.78 to $1,182.73, which is below the average analyst consensus price target of $1,268.94. The company enjoys a strong analyst consensus rating of 'Buy', with a high price target of $1,400 and a low target of $1,119, reflecting significant confidence in the company's growth prospects after becoming the first pharmaceutical company in history to reach a $1 trillion market capitalization.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
Koundeo (scientifically known as orforglipron) is an innovative oral treatment recently approved by the US FDA for weight management and obesity. The drug represents a paradigm shift as the first oral GLP-1 receptor agonist taken as a pill at any time of day without food or water restrictions, making it easier to use compared to traditional injections. The company plans to submit its approval application for type 2 diabetes in the US in late Q2 2026 based on successful ACHIEVE trials.
Sales of Mounjaro and Zepbound (referred to as Suven in some markets) achieved combined global sales of $12.8 billion during the first quarter of 2026 alone. This strong performance contributed a $6.7 billion increase in growth compared to the corresponding quarter in 2025, driving the company's total revenue growth by 56%. Zepbound prescriptions experienced accelerated growth in the US, supported by self-pay channels which represented 45% of total prescriptions in the first quarter.
Eli Lilly raised its full-year 2026 financial guidance as a result of the exceptional performance of its product portfolio in the first quarter. The company now expects annual revenue to range between $82 billion and $85 billion, an increase of $2 billion at both the lower and upper bounds, representing 28% growth compared to 2025. It also raised its non-GAAP EPS guidance to be between $35.50 and $37.00 per share.
Automated analysis for informational purposes only — not investment advice.
Retatrutide showed highly promising results in the Phase 3 TRANSCEND T2D-1 trial for type 2 diabetes patients, reducing HbA1c by 1.7 to 2.0 percentage points. It also helped patients achieve impressive weight loss ranging from 11.1 to 16.6 kilograms (equivalent to 25 to 37 pounds) depending on the dose used. The company expects to announce results from another 80-week obesity trial later this quarter to bolster the profile of this promising drug.
The Centers for Medicare & Medicaid Services (CMS) announced the extension of the Medicare GLP-1 bridge program to provide coverage for obesity drugs to eligible seniors from July 1, 2026, through December 2027. This program helps reduce out-of-pocket costs for senior patients to just $50 per month, enhancing treatment adherence and continuity. Eli Lilly's management expects this extension to contribute to a sustainable increase in sales volume and build a strong patient base ahead of regulatory discussions for 2028.